Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...
Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...
Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
Hosted on MSN
Pfizer inks $530M deal for Novavax Matrix-M adjuvant technology to boost vaccine pipeline
Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) moved to tighten its grip on one of biotech’s hottest disease areas, striking a $50.00 million licensing deal with Pfizer that could ...
NEW YORK(AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results